Lung Cancer
Ideaya Biosciences, Amgen Starting Phase I/II Trial of Targeted Treatment Combo in MTAP-Null Tumors
The US Food and Drug Administration cleared the firms' investigational new drug application to evaluate IDE397 plus AMG193 in an Amgen-sponsored trial.
Freenome Acquires Cancer Dx Firm Oncimmune
Oncimmune offers its CE-marked EarlyCDT Lung blood test, an autoantibody platform, and a research and development pipeline of more than seven cancer detection signatures.
AstraZeneca Sees New Lung Cancer Indication for Tagrisso, Chemo in FLAURA2 Data
Based on high-level results from the trial, the firm believes the combination could be a new first-line option for patients with advanced EGFR-mutated NSCLC.
Researchers want drugmakers to clinically test a predictive model that early studies have shown can determine if a patient's tumor is truly dependent on the KRAS pathway.
NICE Recommends Novartis' Tafinlar-Mekinist as Frontline Treatment for BRAF-Mutant NSCLC
The agency estimated that the drug combination's cost-effectiveness falls within what it considers an acceptable use of the NHS's resources.